Andere talen PharmaTher Holdings Ltd.

Aandelen

PHRM

CA71716H1082

Beurs gesloten - Canadian Securities Exchange Andere beurzen 21:59:59 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,24 ^CAD	-2,04%		+14,29%	-23,81%

23/04	PharmaTher Holdings Ltd. Rapporteert resultaten voor het derde kwartaal en de negen maanden eindigend op 29 februari 2024	CI
16/04	PharmaTher Holdings Ltd. Geeft een update van haar Priority Original Abbreviated New Drug Application voor Ketamine	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

PharmaTher Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	23/04
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	18/04
PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine	16/04
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	16/04
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	16/04
PharmaTher Provides Update For PD-001	21/02
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia	21/02
CapitalGainsReport: Foreign Stocks Under .2 With Growing Potential (TBRIF, BRHCF, FFNTF, PHRRF)	15/02
PharmaTher Provides Update on its Priority Original Abbreviated New Drug Application For Ketamine	12/02
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	12/02
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	12/02
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	12/02
PharmaTher Holdings Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	27/01
PharmaTher Provided Update for Expected FDA Approval of Ketamine	10/01
PharmaTher Provides Update for Expected FDA Approval of Ketamine	10/01
PharmaTher Holdings Ltd. Provides an Update for Its Lead Drug, Ketamine	10/01
PharmaTher Holdings Ltd. Reports Earnings Results for the First Quarter Ended August 31, 2023	31-10-23
PharmaTher Holdings Ltd. Reports Earnings Results for the Full Year Ended May 31, 2023	29-09-23
PharmaTher Announced FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for Ketarx	27-09-23
PharmaTher Brief: Notes FDA assigns GDUFA goal date of April 29, 2024	27-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen PharmaTher Holdings Ltd.

Aandelen

PHRM

CA71716H1082

Andere talen

Filters